Filter posts

The Washington Post Unfairly Attacks The Orphan Drug Act

The Orphan Drug Act has been a tremendous success and addressed a market failure by …

Orphan Drug Tax Credit is Crucial to Rare Disease R&D

The term “rare disease” may be misleading: to be “rare” a disease must effect fewer …

Complexities of Rare Diseases Take the Spotlight at BIO

Global Genes Founder & CEO Nicole Boice opened the BIO 2015 Orphan & Rare Disease …

E&Y Study: 3 Tax Tweaks that Could Spur Job Growth

A new report from Ernst & Young illustrates the economic impact of three tax proposals …

CSBI: New Study Outlines Potential Impact of Three Promising Tax Proposals

Ernst & Young recently released a study to determine the potential impact of three tax …

Propel Small Business Innovation through Tax Reform

As CEO of an emerging clinical-stage biotech company, I lose over $10 million each year. …

Ernst & Young's Beyond Borders: Matters of Evidence

Hundreds of attendees turned out to glean insights from findings outlined in Ernst & Young …

Convention Veterans Putting the “Super” in Super Sessions

Featured in the BIO Buzz Center at last year’s Convention, two of our Super Session …

BIO 2012 Super Session Recap: Ernst & Young’s Beyond Borders

The fanfare surrounding this morning’s unveiling of Ernst & Young’s 26th annual report on the …

2011 BIO International Convention Super Sessions

2011 BIO International Convention Super Sessions Focus on State of the Industry C-Level speakers lead …